RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Omecamtiv Mecarbil: Phase 2 Study Shows No Improvement in Dyspnea AHF But Trend for Further Exploration
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 15
SP 16
OP 17
DO 10.1177/155989771315011
UL http://mdc.sagepub.com/content/13/15/16.abstract
AB The Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure trial [ATOMIC-AHF; NCT01300013], was a Phase 2 dose ranging study which aimed to evaluate the safety, pharmacokinetics and pharmacodynamics, and efficacy of intravenous (IV) omecamtiv mecarbil (OM) in patients with acute heart failure (AHF). The investigators hypothesized that =1 dose of IV OM would be well tolerated and improve dyspnea in patients with left ventricular systolic dysfunction hospitalized for AHF.